

# Comparing CFS, Post-Viral Syndromes, Astronaut Reconditioning, and Neurasthenia

## Introduction

Chronic fatigue syndrome (CFS, also known as ME/CFS), post-viral fatigue syndromes (exemplified recently by “long COVID”), physiological deconditioning after long-duration spaceflight, and the historical condition once termed *neurasthenia* all involve profound fatigue and multi-system dysfunction. At first glance these may seem disparate: one is a chronic illness of unclear etiology, another a sequela of viral infection, a third a reversible adaptation to microgravity, and the last a 19th-century nervous malady. Yet, striking parallels emerge in their symptoms, affected organ systems, and the body’s maladaptive responses. Each presents a complex tapestry of dysfunction involving the brain, autonomic nervous system, endocrine stress axes, immune system, energy metabolism, and even the gut. At the same time, important differences in triggers, time course, and treatment responses distinguish them. This narrative synthesis will compare these conditions along key physiological axes – gastrointestinal (GI) disturbance, autonomic nervous system (ANS) dysregulation, hypothalamic-pituitary-adrenal (HPA) axis changes, mitochondrial/energy deficits, and immune/inflammatory activity – and examine their recovery patterns and therapies, from Victorian rest cures to modern rehabilitation. The goal is to identify common threads suggesting unified mechanisms of chronic, multi-system dysfunction and to highlight divergent features that yield insights into each condition’s nature.

## Multi-System Involvement: Physiological Parallels and Contrasts

**Gastrointestinal and Microbiome Aspects:** A notable overlap among these conditions is involvement of the GI system, often in the form of dysregulated gut function or microbiota. In CFS, up to 38–42% of patients fulfill criteria for irritable bowel syndrome and over 70% report chronic gastrointestinal disturbances <sup>1</sup>. Studies consistently show an altered gut microbiome in ME/CFS, with reduced microbial diversity and shifts such as a lower Firmicutes-to-Bacteroides ratio and depletion of butyrate-producing bacteria <sup>2</sup> <sup>1</sup>. This dysbiosis is believed to contribute to a “leaky gut” and systemic inflammation via a disturbed gut-brain axis <sup>3</sup>. Post-infectious fatigue syndromes similarly exhibit GI involvement. In long COVID (a prototypical post-viral syndrome), about 20% of patients have persistent diarrhea and ~14% report loss of appetite many months after the acute infection <sup>4</sup>. Overall, around 29% of long COVID patients experience some GI symptomatology 6 months post-infection, including reflux (16%), constipation (11%), diarrhea (10%), and nausea <sup>5</sup>. Mechanistic studies implicate long-lasting changes in gut flora – for example, long COVID patients show enriched *Bacteroides* and *Ruminococcus gnavus* and depleted *Faecalibacterium prausnitzii*, alongside lingering SARS-CoV-2 antigens in the gut mucosa <sup>6</sup> <sup>7</sup>. These findings mirror the microbiome aberrations seen in CFS and suggest a common theme of a persistent gut dysbiosis driving inflammation and symptoms across chronic post-viral and idiopathic fatigue states.

Astronauts returning from space also demonstrate transient but notable GI and microbiome changes due to microgravity. Spaceflight alters the composition of the gut microbiota in both rodents and humans, with experiments on the International Space Station showing shifts (e.g. increased Firmicutes:Bacteroidetes ratio

in mice) and changes in microbial metabolites such as short-chain fatty acids <sup>8</sup> <sup>9</sup> . Unlike in CFS or long COVID, these changes in astronauts are usually reversible: post-flight analyses indicate that the gut microbiome profile returns toward pre-flight baseline within days to weeks after re-entry to Earth's gravity <sup>10</sup> . Nevertheless, the fact that microgravity so readily perturbs the gut ecosystem underscores the sensitivity of this “virtual organ” to systemic stress. Historical neurasthenia also had a significant gastrointestinal dimension. Victorian physicians frequently described *nervous dyspepsia* (indigestion) as a core feature – in many cases “the first noticeable symptom of nervous exhaustion,” as George Miller Beard (who popularized neurasthenia in 1869) observed <sup>11</sup> . Entire subcategories like *neurasthenia gastrica* were devoted to patients whose fatigue and melancholy were accompanied by prominent GI complaints <sup>12</sup> . Some late 19th-century doctors even posited “auto-intoxication” from the gut – toxins from sluggish bowels poisoning the nervous system – as a cause of neurasthenic symptoms <sup>12</sup> . In modern terms, they intuited a brain-gut connection that current research on the microbiome and inflammation is now exploring in CFS and related conditions. Thus, from chronic fatigue patients with leaky gut and altered flora, to astronauts and neurasthenic patients with “nervous stomach,” disruptions of GI homeostasis appear as a recurrent motif.

**Autonomic Nervous System (ANS) Dysregulation:** Another common axis of dysfunction is the autonomic nervous system, which regulates heart rate, blood pressure, digestion, and other unconscious processes. Orthostatic intolerance (difficulty maintaining blood pressure upon standing, leading to dizziness or fainting) and related dysautonomia are hallmark issues in both ME/CFS and long COVID. Clinical studies find that a large majority of ME/CFS patients – by some estimates 80% or more – experience symptoms of autonomic dysfunction such as lightheadedness, palpitations, neurally mediated hypotension, and **postural orthostatic tachycardia syndrome (POTS)** <sup>13</sup> . In one cohort, 83% of CFS patients reported chronic dizziness/instability and 79% had orthostatic hypotension episodes <sup>13</sup> . Objective testing often confirms altered heart rate and blood pressure control, and subsets of patients show either sympathetic over-activation or, in severe cases, sympathetic withdrawal with parasympathetic excess <sup>14</sup> . The severity of autonomic symptoms in CFS correlates with fatigue severity and poor quality of life <sup>15</sup> <sup>16</sup> , suggesting dysautonomia is central to the illness rather than a coincidental comorbidity. Long COVID patients are showing a very similar pattern. Multiple studies indicate that anywhere from roughly 46% to over 60% of long COVID sufferers have evidence of autonomic dysfunction months after infection <sup>17</sup> . One report found 67% of a large sample met criteria for dysautonomia by symptom score <sup>17</sup> . POTS – characterized by excessive heart rate increase on standing – has gained particular attention as a frequent post-COVID complication, especially in younger patients. In essence, the SARS-CoV-2 virus appears to precipitate a dysautonomic state in a substantial subset, likely via mechanisms like neuropathy of autonomic fibers, persistent inflammation, or autoimmune effects on autonomic receptors <sup>18</sup> . This mirrors what has long been observed in post-viral CFS and other post-infectious syndromes (for example, autonomic “failure” was noted in survivors of the 1918 influenza and other epidemics), strengthening the link between long COVID and CFS/ME on a pathophysiological level.

Spaceflight-induced deconditioning provides a fascinating analog of autonomic dysfunction under a completely different trigger – prolonged weightlessness. Upon returning to Earth's gravity, astronauts commonly experience orthostatic intolerance due to a combination of reduced blood volume, vascular deconditioning, and baroreflex changes. In fact, without countermeasures, **orthostatic hypotension** can be nearly universal after long missions. A modeling study notes that approximately 20–30% of astronauts from short Shuttle flights (a week or two) had orthostatic intolerance, whereas **~80% of astronauts** after long-duration International Space Station (ISS) missions experienced significant orthostatic symptoms on return <sup>19</sup> . (For comparison, only ~5% of healthy people under 50 have such issues <sup>19</sup> .) This manifests as

dizziness, fainting, and inability to stand for more than a few minutes – not unlike a severe POTS patient on Earth. The cause in astronauts, however, is clearly related to the adaptive responses to microgravity: fluid shifts upward, the heart and vestibular system recalibrate to no “up-down” orientation, and over time the body downregulates plasma volume and vascular tone since less is needed in zero-G. Upon re-entry, gravity brutally unmasks these changes. The situation is acute but usually short-lived: with volume loading (saline, fluids), compression garments, and reconditioning exercises, astronauts generally recover normal orthostatic tolerance within days to a couple of weeks. Still, the *mechanistic* overlap with CFS and long COVID is intriguing – in all cases, the autonomic circuitry controlling circulatory reflexes is disturbed, leading to similar symptoms. Neurasthenia, too, often included what we would now call autonomic complaints. Nineteenth-century descriptions of neurasthenic patients mention “*palpitations*”, labile blood pressure, vasomotor flushes, sweating, fainting spells and other signs that today might suggest dysautonomia <sup>20</sup> . Terminology differed, but a neurasthenic with “nervous heart” and dizzy spells might well have had POTS or orthostatic hypotension by modern criteria. Thus, across all four conditions, a thread of ANS imbalance – whether from viral injury, immune signaling, physical deconditioning, or “nervous exhaustion” – emerges as a common contributor to fatigue and exercise intolerance.

**HPA Axis and Neuroendocrine Changes:** The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system, and evidence suggests it is perturbed in chronic fatigue conditions and in post-stress reconditioning states. In CFS/ME, decades of research have documented subtle but significant alterations in HPA-axis function. The consensus is that CFS patients typically exhibit a state of **mild hypocortisolism with blunted dynamic responsiveness** <sup>21</sup> <sup>22</sup> . Cortisol (the end hormone of the HPA axis) tends to be low-normal or slightly low, with a flattened diurnal rhythm – the usual peak in the early morning and decline in evening is less pronounced <sup>21</sup> . There is often an *enhanced negative feedback* sensitivity (the HPA axis shuts off more easily) and an inadequate cortisol rise in response to stressors <sup>21</sup> . In practical terms, the adrenal output in CFS seems “limp” – potentially a downstream consequence of chronic activation earlier in the illness. These findings have clinical relevance: lower cortisol correlates with worse fatigue and symptoms <sup>23</sup> , and some studies found that patients with the lowest cortisol had the poorest responses to therapy <sup>23</sup> . Notably, these changes are more consistently observed in female patients <sup>24</sup> , aligning with the higher prevalence of CFS in women. The etiology is multifactorial – prolonged stress, pain, sleep disruption, and even childhood trauma in some cases may drive the HPA axis into a “burned-out” state <sup>25</sup> . Importantly, this pattern (low cortisol, blunted circadian variation) is *not* seen in healthy sedentary persons, so it is not simply deconditioning. It echoes a phenomenon of “adrenal exhaustion” or allostatic overload: initially high stress hormone output during acute illness or stress, followed by a downregulated axis in the chronic phase. Recent studies in long COVID indicate a very similar HPA-axis signature. In one cohort over a year post-COVID, **cortisol levels were about half that of healthy controls** – by far the most distinguishing biochemical abnormality found – suggesting a hypocortisolemic state in long COVID survivors <sup>26</sup> . This low cortisol in long COVID mirrors the pattern long noted in CFS <sup>27</sup> , reinforcing the kinship of the two conditions. The causes in long COVID are still under investigation, but may include direct effects of the virus on adrenal or pituitary tissue, autoimmune adrenalitis, or prolonged immune-related feedback on the HPA axis <sup>28</sup> <sup>29</sup> .

In striking contrast, astronauts in space experience *activation* of the HPA axis and sympathetic “fight-or-flight” system during missions – essentially the opposite phase of what we see in chronic illness. The unusual environment of space (microgravity, confinement, radiation, disrupted circadian cues) is a potent stressor. Astronauts have consistently shown elevated catecholamines (epinephrine, norepinephrine) and sometimes **elevated cortisol levels during spaceflight** <sup>30</sup> . For example, salivary cortisol measurements in ISS crew members found significantly higher cortisol during flight (while DHEA, an adrenal androgen, was

decreased) compared to pre- or post-flight <sup>30</sup> <sup>31</sup> . The *diurnal pattern* of cortisol can also shift – some astronauts develop a phase delay or flattening of the cortisol curve in space due to altered light/dark cycles and sleep schedules <sup>32</sup> . This neuroendocrine stress response in microgravity is believed to contribute to various phenomena: immune suppression and latent virus reactivations (half of astronauts on long missions shed Epstein-Barr, varicella, or other herpesviruses, linked to stress hormone elevations) <sup>30</sup> <sup>33</sup> , as well as bone and muscle catabolism. Upon return to Earth, cortisol and adrenaline levels normalize fairly quickly as the acute stress resolves. Thus, astronauts illustrate the “acute” phase of stress response (high HPA/SNS activity), whereas CFS/ME and long COVID represent a chronic phase where the system may be dampened or dysregulated after long-term stress. Neurasthenia, in the absence of hormone assays in that era, was conceptualized in HPA-like terms: it was literally defined as a depletion of “nervous force,” akin to adrenal or nervous system burnout from chronic overexertion <sup>34</sup> <sup>35</sup> . Some late-1800s physicians even used the language of exhaustion of the nerve centers due to stress of civilization (fast-paced “modern life” was blamed for draining people’s vitality) <sup>35</sup> <sup>36</sup> . In modern hindsight, one might say neurasthenia patients probably had chronically altered stress hormone profiles as well – though they couldn’t measure cortisol, they recognized a state of collapse following prolonged pressure. In summary, all these conditions involve an HPA axis component: revved up in the acute phase (astronauts in orbit, acutely viral-infected patients), but tending toward dysfunction or insufficiency in the chronic phase (CFS, long COVID, neurasthenia), with consequent impacts on energy, immunity, and homeostasis.

**Mitochondrial and Cellular Energy Metabolism:** Perhaps the most unifying thread linking these diverse scenarios is disturbance in cellular energy production – namely, mitochondrial function. Fatigue, at its core, suggests that the body’s cells are not efficiently generating or utilizing energy. Modern research into CFS/ME has increasingly focused on metabolic and mitochondrial abnormalities. A landmark metabolomics study in 2016 found that **CFS patients are in a hypometabolic state reminiscent of dauer/hibernation** – their blood metabolite profile indicated systematically lower levels of various metabolites and evidence of a coordinated downshift in ATP-generating pathways <sup>37</sup> . The authors concluded that *“chronic fatigue syndrome is a highly concerted hypometabolic response to environmental stress that traces to mitochondria,”* akin to a chronic switch into an energy-conserving mode <sup>37</sup> . Supporting this, other studies have reported impaired mitochondrial ATP production in muscle cells of CFS patients and greater accumulation of lactate after exercise, suggesting a cellular energy deficit. Mitochondrial enzymes and genes may be downregulated in some patients, and an excess of oxidative stress markers points to inefficient or strained respiration. Post-viral fatigue conditions appear to operate similarly: for instance, muscle biopsies from SARS survivors in 2003 showed mitochondrial swelling and dysfunction months after infection, and early data in long COVID patients suggest an altered oxidative phosphorylation capacity in immune cells.

It is fascinating, then, that NASA investigators recently converged on mitochondria as the “universal” trigger of physiological problems in astronauts. In 2020, a large analysis of astronaut data (the NASA GeneLab studies, including the Twins Study) revealed that **many spaceflight-induced changes in different organs traced back to mitochondrial dysregulation** <sup>38</sup> . Liver, muscle, and immune cells from astronauts in orbit showed altered expression of mitochondrial genes and evidence of reduced energy output <sup>39</sup> <sup>40</sup> . As one NASA scientist noted, “whether we were looking at problems in the eyes or in the liver, the same pathways related to mitochondria were the source of the problem” <sup>38</sup> . Microgravity might directly impair mitochondrial dynamics via altered fluid shear, radiation, and stress hormone effects, leading to a cascade of issues (insulin resistance, muscle atrophy, immune dysfunction). The NASA team went so far as to say *“everything gets thrown out of whack and it all starts with the mitochondria”* <sup>41</sup> <sup>42</sup> . This statement could apply almost equally well to ME/CFS research hypotheses. In both cases, mitochondria – the cellular “powerhouses” – appear to respond to an initial trigger (viral infection or microgravity stress) by entering a

dysfunctional state, which in turn contributes to systemic symptoms. Neurasthenia's very metaphor was a lack of "nerve force" and a depleted "battery" of energy. While Victorian doctors did not know of mitochondria, they were effectively describing a chronic low-energy syndrome. Some even tried dietary supplements (the meat-rich, high-fat diet in the rest cure) in an attempt to rebuild energy stores <sup>43</sup>. Thus, across time and contexts, impaired bioenergetics is a recurring theme – whether conceptualized as low ATP, metabolic shutdown, or nervous exhaustion – tying these conditions together. Each can be seen as a state of mismatched energy demand and supply, with mitochondria at the nexus of the problem.

**Immune Activation and Inflammation:** Immune system dysfunction is another shared feature, though its expression differs by context. CFS/ME has long been theorized to involve a chronic immune activation or inflammatory state, often subtle but discernible. Many patients report that their illness began with an infectious-like episode, and researchers have found various immune irregularities: for example, elevated pro-inflammatory cytokines (like IL-6, IL-8, interferon-gamma) in patients with more severe CFS <sup>44</sup> <sup>45</sup>, and an **immune "signature" of about 17 cytokines correlating with CFS disease severity** (13 of which are pro-inflammatory) <sup>44</sup>. This indicates that more severely affected patients have an ongoing inflammatory drive <sup>45</sup>. Other studies have noted reduced function of natural killer cells, shifts in T cell populations, and the presence of autoantibodies in subsets of patients. While no single cytokine or marker is uniformly abnormal in all CFS cases (results have been inconsistent between studies <sup>46</sup> <sup>47</sup>), a reasonable summary is that CFS involves a state of chronic immune dysregulation or "simmering" neuroinflammation <sup>48</sup> <sup>49</sup>. This may be the cause of, or response to, the underlying pathology – likely both, in a vicious cycle. Patients certainly experience "sickness behavior" symptoms (fatigue, malaise, cognitive fog) that reflect immune cytokine effects on the brain. Post-viral syndromes like long COVID make the immune link even more apparent: these conditions *begin* with a virus, and a leading hypothesis is that fragments of virus or dysregulated immune responses persist, driving ongoing symptoms. Indeed, long COVID patients sometimes show elevated inflammatory markers (e.g. C-reactive protein or certain interleukins) and reduced levels of cortisol's anti-inflammatory influence <sup>28</sup> <sup>26</sup>, creating a milieu skewed toward inflammation. Autonomic nerves can be inflamed as well (some long COVID patients have evidence of small-fiber neuropathy affecting autonomic fibers <sup>18</sup>). Notably, one study found *expansion of cytotoxic T cells associated with the GI manifestations of long COVID* <sup>50</sup>, hinting that persistent immune activation in tissues (like gut or brain) could underlie symptom clusters. Parallels to CFS are abundant – for example, both long COVID and CFS can involve elevated TGF-beta and IL-10 (immunoregulatory cytokines) and reduced function of certain T-cell subsets <sup>46</sup> <sup>47</sup>. In essence, the immune system in these chronic syndromes appears to be stuck in an intermediate state: not aggressively fighting a specific pathogen, but also not fully "resetting" to normal. This condition of immune noise or smoldering inflammation likely contributes to symptoms (fatigue, pain, brain fog) and can further perturb the HPA axis and ANS (since cytokines influence both).

Spaceflight presents a bit of a twist: in orbit, *immune function is often suppressed* – astronauts frequently show decreased T-cell activation, blunted vaccine responses, and reactivation of latent viruses as mentioned <sup>33</sup>. This is due to a combination of stress hormones (cortisol and adrenaline are immunosuppressive short-term), radiation effects on immune cells, and perhaps microgravity directly altering cell signaling. Up to half of astronauts have some level of immunodeficiency on landing <sup>51</sup>, though it usually normalizes within days or weeks back on Earth. Intriguingly, the recovery from space triggers a rebound of immune activity; some astronauts experience transient inflammation and overactive immune responses after re-exposure to gravity (a kind of immune reconstitution). So whereas CFS and post-viral patients deal with chronic low-grade *activation*, astronauts cycle from suppression to reactivation. Still, the concept of immune dysregulation is common to all. Even neurasthenia had its immune theory variant: some physicians hypothesized chronic infections or "blood poisoning" as causes of neurasthenia in certain cases, and the

diagnosis overlapped with what we'd now call chronic infections (e.g. occult tuberculosis or syphilis sometimes were mislabeled as neurasthenia before their definitive tests were known). More generally, neurasthenic patients often reported flu-like malaise, tender lymph nodes, sore throats, etc., akin to the post-infectious features in today's ME/CFS definitions <sup>52</sup>. One might speculate that many neurasthenia cases were post-viral fatigue states following illnesses like influenza, since there were waves of "grippe" and other infections in that era that left people drained. In summary, a dysregulated immune system – whether in overdrive or underperforming – and the resultant inflammation or lack thereof, is a key piece of the puzzle across these conditions. This immune component ties into other systems (gut permeability, HPA axis suppression, etc.), reinforcing the concept of a network disturbance.

**Summary:** Despite obvious differences between an astronaut returning from space, a long COVID patient, a classic ME/CFS patient, and a neurasthenic individual from 1890, the physiological patterns show remarkable commonalities. All involve *multi-system* dysregulation – the gut-brain axis, autonomic circulation control, stress hormone dynamics, cellular energy metabolism, and immune status are all perturbed. The differences tend to be in degree and timeline: astronauts have acute, externally-induced changes that are largely reversible; CFS and post-viral patients have chronic, self-perpetuating changes that can last years or a lifetime; neurasthenia occupied an intermediate view – often chronic but considered curable with rest and removal of stress. The multi-system nature of these syndromes suggests that no single organ "fails." Rather, there is a breakdown in the normal *integration* of bodily systems – a kind of systems biology problem where communication between the brain, gut, immune system, endocrine glands, and muscles has gone awry. Modern researchers often invoke the idea of a chronic allostatic load or a maladaptive "locked" state (e.g. the cell danger response in CFS) to explain how an initial trigger (infection, stress, microgravity) can lead to a sustained condition of ill health <sup>37</sup>. In the next sections, we will see how these shared dysfunctions play out in clinical course and recovery, and how treatments have evolved from the era of rest cures to today.

## Symptoms, Recovery Trajectories, and Outcomes

**Symptom Profiles and Overlaps:** All four conditions share the central symptom of severe fatigue/exertional intolerance, but the nuance of symptom profiles shows some divergence. **Chronic fatigue syndrome (ME/CFS)** is characterized by debilitating fatigue lasting at least 6 months, *post-exertional malaise* (PEM) – a hallmark where even minor physical or mental exertion can trigger a crash of intensified symptoms a day or two later – and unrefreshing sleep. Cognitive difficulties ("brain fog"), headaches, muscle and joint pain, and orthostatic symptoms are also common diagnostic features <sup>53</sup> <sup>54</sup>. Many CFS patients experience significant pain and neurocognitive issues in addition to fatigue, indicating a broad impact on the central nervous system. Notably, while routine exercise typically improves fitness in healthy individuals, in ME/CFS even mild exercise can **worsen** the condition (this is the phenomenon of PEM), which is an important point of contrast with pure deconditioning states. **Post-viral syndromes** such as long COVID often mimic the symptom complex of CFS to a remarkable degree. Long COVID patients frequently report profound fatigue (in one international study, 80% had fatigue at 6 months) and post-exertional symptom exacerbation (73% reported post-exertional weakness) <sup>55</sup> <sup>56</sup>. They also manifest cognitive impairments (difficulty with memory and multitasking), sleep disturbances, autonomic symptoms (palpitations, POTS, temperature dysregulation), and pain (chest pain, joint aches) – many of the same complaints long voiced by the ME/CFS community. One difference is that long COVID often presents with more organ-specific damage in some cases: for instance, a subset have persistent lung function deficits, abnormal cardiac MRI findings, or renal impairment as sequelae of the acute viral damage. But in patients without clear organ injury, long COVID is essentially a multi-system functional disorder that is hard to distinguish from CFS <sup>57</sup>. Indeed, a systematic review found "considerable similarities and few differences" between ME/CFS and long

COVID symptomatology and biology <sup>57</sup> . One modest difference is that long COVID patients more often report loss of smell, lingering cough or breathing difficulties (as expected from a respiratory virus), whereas classic CFS (often triggered by Epstein-Barr virus or other non-respiratory infections) might have less of those specific symptoms. Nonetheless, the overlap is so significant that experts consider long COVID as a potential precipitant of ME/CFS – in fact, new-onset ME/CFS may be one outcome of long COVID in a fraction of patients <sup>58</sup> <sup>59</sup> .

**Astronaut reconditioning** after long missions, on the other hand, involves a suite of symptoms that are more predictable given the known physiological changes. Immediately on landing, astronauts often experience vertigo, dizziness, and faintness when standing (from orthostatic intolerance as discussed), as well as generalized weakness and motor coordination difficulties. Their muscles, having atrophied in microgravity despite exercise, are detrained – especially the postural muscles and lower limb extensors. This leads to quick fatigue on walking and a shakiness in movements. Balance and gait can be affected due to vestibular recalibration; returning crew may walk with a wide stance and need support to avoid falling. They sometimes describe a “heavy” feeling of limbs as gravity pulls on them again. Sleep patterns may be disrupted (some develop significant sleep debt or circadian misalignment during missions). There can also be visual changes (from fluid shifts affecting eye shape) and, less commonly, lingering back pain from spinal discs re-compressing after the microgravity-induced spinal lengthening. Unlike CFS or long COVID, astronauts generally **do not** complain of cognitive “brain fog” or widespread pain – their symptoms are more purely orthostatic and musculoskeletal, reflecting a primarily physical deconditioning. Psychologically, astronauts are usually in high spirits after missions, and while they must readapt to normal sensory inputs, they typically do not report the kind of crushing fatigue or neuro-sensory overload that ME/CFS patients do after exertion. In short, the symptom overlap with chronic fatigue conditions is present (fatigue, dizziness, weakness), but astronauts lack the inflammatory or neurocognitive facets, and their fatigue improves rapidly with reconditioning rather than worsening with activity.

**Neurasthenia**, in its heyday (1880s–1920s), had a broad array of symptoms spanning the mental and physical. Common complaints included persistent fatigue/listlessness, diffuse aches, headaches (especially “pressure” headaches), poor sleep or insomnia, difficulty concentrating, memory lapses, irritability or low mood (without the complete loss of pleasure that defines modern major depression), and often numerous somatic symptoms: e.g. *back pain (“spinal irritation”), palpitation, indigestion, constipation, sexual dysfunction or loss of libido, fainting spells, tinnitus*, and so on <sup>34</sup> <sup>20</sup> . It was sometimes called the “weak heart, weak stomach, weak nerves” syndrome. The multiplicity of neurasthenic symptoms is reminiscent of what we now call somatic symptom disorder or a mix of chronic fatigue with fibromyalgia and anxiety. In fact, many neurasthenia cases would overlap with today’s criteria for fibromyalgia (due to the pain and fatigue) or generalized anxiety disorder (due to constant worry and bodily preoccupation) – and indeed neurasthenia’s demise as a diagnosis came as psychiatry split these into different categories. Nevertheless, the core feature was an enduring fatigue not relieved by rest, much like CFS, and a sense of being “shattered” by effort. One distinguishing aspect was that neurasthenia was often linked to *mental overwork* or stress in addition to (or instead of) viral illness or physical deconditioning. Patients were often described as having driven themselves too hard in business, study, or social life, leading to collapse. Because of this, neurasthenic fatigue was often accompanied by anxiety, depression, or emotional fragility, which in some cases might have actually been primary (what we’d now view as depression with fatigue). Still, many historical reports clearly depict what sounds like post-infectious or post-traumatic fatigue syndromes under the neurasthenia label. For example, physician reports from post-Civil War America described young men with “soldier’s heart” or “irritable heart” (likely PTSD plus dysautonomia) who were folded into neurasthenia

diagnoses. The symptom pattern in those cases – exercise intolerance, tachycardia, lightheadedness, fatigue – is a direct mirror of CFS/POTS cases today, just described in Victorian prose.

**Recovery Timelines:** The natural history of these conditions varies widely. **ME/CFS is typically a chronic, often lifelong illness**, though degrees of improvement occur. Studies and clinical observations suggest that a minority of adults fully recover; many have a relapsing-remitting course or plateau at a reduced level of function. Montoya et al. noted that spontaneous recoveries are uncommon after the first year of illness, and “rarely after the condition has persisted more than five years” <sup>60</sup>. Pediatric cases of CFS, however, often have a better prognosis, with a substantial portion improving by early adulthood, possibly due to greater physiological resilience. Overall, long-term follow-ups indicate that perhaps 20% of adult CFS patients might experience remission at some point, but the majority continue to have some symptoms indefinitely, and a significant subset remain severely impaired for decades. **Post-viral syndromes** can show more recovery, depending on the virus and patient. For long COVID, data are still emerging, but encouragingly a two-year follow-up study in China found the prevalence of any long COVID symptoms dropped from 68% at 6 months to 55% at 2 years post-infection <sup>61</sup>. Notably, the proportion with fatigue/weakness fell from 63% at 6 months to 30% at 2 years <sup>62</sup>. This suggests that roughly half of those with initial post-COVID fatigue had significant improvement by 24 months, although 30% still having fatigue is not trivial. We also see improvement in specific organ sequelae over time (e.g. lung diffusion capacity tends to recover partially by 1–2 years). Nevertheless, a subset of long COVID patients appear to transition into a chronic ME/CFS-like state that may not yet have an endpoint. Other post-viral syndromes historically show variable timelines: post-Epstein Barr fatigue (after mononucleosis) often lasts 6–12 months in adolescents but can sometimes become chronic; post-Ebola or post-SARS-1 syndromes in survivors lasted several years in many cases, with some gradual improvement observed. The key point is that post-viral fatigue *generally trends toward improvement* over time – the immune system gradually recalibrates and any reversible changes slowly normalize – but some individuals are left with permanent or very long-term illness. This contrasts with idiopathic CFS, where there was no identifiable “end” of a viral trigger and hence no clear timeline at all; such cases can be static or progressive.

**Astronaut reconditioning** follows a much faster and more predictable timeline. NASA's standard rehabilitation protocol for ISS astronauts is about **45 days** of intensive reconditioning, by the end of which “the majority of astronauts are returned to baseline condition” <sup>63</sup>. In fact, significant recovery occurs in the first 1–2 weeks: cardiovascular and neurovestibular functions rebound quickly with fluid and salt replacement and re-exposure to gravity. Muscle strength and endurance typically take a few weeks of exercise training to rebuild. A mission of six months can cause on the order of 10–20% loss in muscle cross-sectional area and similar drops in peak  $\text{VO}_2$ ; these tend to normalize within a month or two of rigorous exercise post-flight. Bone density is the slowest to recover – weight-bearing bone (spine, hip) loses ~1–2% per month in microgravity despite countermeasures, and after return it can take many months to lay down new bone, if it happens at all. Some studies suggest incomplete recovery of bone mineral even after a year back, meaning astronauts might carry a slightly elevated long-term osteoporosis risk <sup>64</sup> <sup>65</sup>. However, functionally, astronauts are usually back to normal daily activities within days and back to mission-ready fitness by 1–2 months. There are exceptions (occasional injuries or prolonged dizziness), but nothing like the open-ended uncertainty of chronic fatigue illnesses. The determinants of recovery here are straightforward biology – muscle protein synthesis, cardiovascular reconditioning – and with youth and training, these processes are efficient. It underscores that when the cause of fatigue is purely disuse and the body's structural integrity is intact, recovery can be full and rapid, in contrast to the more enigmatic chronic cases.



**Neurasthenia's course** was documented in a pre-modern medical context, so hard outcomes are not quantifiable. Many patients apparently did improve with prescribed rest and removal of stress – enough that the “rest cure” enjoyed popularity due to success stories. The typical rest cure was **6–8 weeks** of enforced bed rest, and by most accounts many patients emerged much better at the end <sup>66</sup>. They often gained weight and strength (e.g. one cited case gained 40 pounds in a month on the diet and rest regime <sup>67</sup>) and reported renewed energy, at least in the short term. Some proportion likely had relapses if they went back to the same stressors; others perhaps were essentially cured (especially if the neurasthenia corresponded to a self-limited post-viral state or overwork that, once relieved, did not recur). It is also likely that a number of neurasthenia cases were early manifestations of disorders that do not spontaneously remit – for instance, some patients may have actually had what we'd now call multiple sclerosis or hypothyroidism or clinical depression, and those would not truly be cured by rest (leading to those patients languishing or later being reclassified). But for garden-variety nervous exhaustion of the Victorian era, the prognosis was considered good with proper care. The gender dynamic also played a role: men were often advised a “*West cure*” (outdoor activity, ranching, exercise) and many reportedly felt invigorated by it, suggesting that some were suffering more from a form of depression or burnout that responded to lifestyle change. Women, confined to bed, often chafed at the restriction (Charlotte Perkins Gilman's famous short story “**The Yellow Wallpaper**” is a fictionalized critique of the rest cure, showing a woman descending into psychosis when locked in a room to rest). So the rest cure had its failures too. As the 20th century dawned, neurasthenia increasingly splintered into other diagnoses (anxiety, depression, etc.), each with its own prognosis. In modern terms, those with what we'd identify as ME/CFS among the neurasthenics likely did not fare much better than today's patients if they remained in that condition chronically; others, whose fatigue was due to a passing strain, likely recovered. In short, neurasthenia's recovery timeline was variable, but the prevailing view then was that *months* of rest would lead to recovery – implying they expected it to be curable in a matter of months to a year for many patients, which suggests they were often dealing with reversible functional fatigue states.

## Therapeutic Approaches: From Rest Cures to Rehabilitation



*A 19th-century illustration of a neurasthenia patient on the “rest cure,” being tended by a nurse. This regimen involved weeks of enforced bed rest, isolation, and high-calorie feeding to restore nervous energy.* <sup>66</sup> <sup>43</sup>

**Historical Rest and “Nerve Tonics”:** In the Victorian and Edwardian era, the primary treatment for neurasthenia was *rest, rest, and more rest*. Pioneered by neurologist Silas Weir Mitchell, the “**rest cure**” was a strict protocol usually lasting 6–8 weeks where the patient (often an upper-class woman) was confined to bed in seclusion, with minimal intellectual stimulation or physical activity <sup>66</sup>. A high-fat, high-milk diet was provided liberally – patients were sometimes fed a rich diet of milk, eggs, and meat **every few hours**, aiming for weight gain and improved “blood supply” <sup>43</sup>. Massage and electrotherapy were employed to passively stimulate muscles and circulation in lieu of exercise <sup>68</sup>. This approach rested on the theory that the nerves needed absolute quiet and nutrition to recuperate. As mentioned, the rest cure often led to substantial short-term improvement in fatigue and weight, though at the cost of muscle deconditioning and, in some cases, significant psychological strain from enforced idleness <sup>69</sup> <sup>70</sup>. Alongside bed rest, a plethora of **nerve tonics and patent medicines** were marketed for neurasthenia – everything from coca wine to arsenic compounds and electrical belts <sup>71</sup> <sup>72</sup>. Many contained stimulants (like caffeine, strychnine or small doses of opium) which probably perked up patients temporarily. Hydrotherapy (cold or warm baths), spa retreats, and “change of air” (travel) were also prescribed. Interestingly, for *male* neurasthenics, Mitchell often recommended the so-called “**West cure**” – essentially the opposite of bed rest. Men were sent out to ride horses, hunt, hike, and engage in robust outdoor activity in the American West <sup>73</sup>. This gendered approach was based on the view that neurasthenic men were often weakened by urban sedentary life and needed vigorous exercise to rebuild manliness, whereas women were presumed too fragile and needed confinement. In retrospect, the West cure was akin to modern exercise therapy and likely helped some men who were simply deconditioned or mildly depressed. The rest cure, while out of favor now, likely did benefit a subset of patients who truly needed extended convalescence – for instance, after a mono-like infection or severe burnout, weeks of enforced rest and nutrition could indeed facilitate recovery (much as we prescribe rest in the acute phase of, say, myocarditis or mono today). However, prolonged bed rest also has negatives: muscle atrophy, thrombosis risk, and potential exacerbation of depression. The mixed outcomes of the rest cure eventually led to it being abandoned by mid-20th century, especially as psychoanalysis reframed such symptoms in psychological terms and new psychiatric drugs emerged.

**Graded Exercise vs. Pacing in ME/CFS:** In the latter 20th century, as CFS/ME was being studied, an opposite philosophy took hold: *too much* rest might be detrimental, and gradual exercise might restore function. The idea of **graded exercise therapy (GET)** was that patients should slowly increase their activity levels in a structured way to overcome deconditioning. In theory, this sounds sensible – many chronic illness patients become deconditioned, and exercise can improve cardiovascular fitness and muscle efficiency. Indeed, early small studies and some clinical trials claimed that graded exercise led to modest improvements in CFS fatigue and fitness. However, this became one of the most **controversial aspects** of CFS treatment. Many patients reported that pushing exercise beyond their limits triggered debilitating crashes (confirming the reality of post-exertional malaise), and that a rigid GET program could spiral them into worse health. The large PACE trial (2011) in the UK initially reported that GET and cognitive-behavioral therapy (CBT) yielded improvement in CFS, but in the ensuing years, patient advocacy groups and some scientists criticized the trial’s methods and results heavily. Subsequent re-analyses and the accumulated patient testimony led to a major shift: by 2021 the UK’s NICE guidelines **withdrew the recommendation for graded exercise** in ME/CFS, instead emphasizing “pacing” and gentle, tolerance-based activity only <sup>74</sup> <sup>75</sup>. **Pacing** is essentially the strategy of balancing activity with rest to avoid triggering PEM – patients are encouraged to stay within an energy “envelope” and not push to the point of symptom flare. This approach

aligns with what ME/CFS patients themselves learned anecdotally over years. So, whereas neurasthenia's treatment was all rest and no exertion, ME/CFS treatment evolved into a careful titration of *some* activity but never so much as to precipitate collapse. Notably, in conditions like long COVID, which often include a CFS-like component, clinicians are already cautious about exercise therapy – rehab programs for long COVID typically focus on *interval training* with very gradual increases and incorporate breathing exercises and cognitive rest as needed, essentially a pacing-informed approach. On the other hand, if a post-COVID patient has primarily organ-specific issues (like decreased lung capacity), traditional pulmonary rehab exercise can be beneficial. The crux is that in patients with clear PEM and systemic fatigue, forcing exercise can do harm. This lesson distinguishes ME/CFS and similar syndromes from straightforward deconditioning.

**Integrative and Symptomatic Therapies:** Because no single medication can “cure” these complex syndromes, a wide range of integrative or multimodal approaches are used. In modern ME/CFS management, treatment is individualized and might include: **sleep aids** (to try to improve sleep quality), low-dose **antidepressants or anxiolytics** (for mood or pain modulation – for example low-dose tricyclics can help sleep and pain), **analgesics** (for headache or fibromyalgic pain), **IV saline** or fludrocortisone (to expand blood volume for orthostatic intolerance), **beta-blockers or midodrine** (to manage POTS by slowing heart rate or raising blood pressure), and **dietary supplements** thought to support mitochondrial function (like CoQ10, B-vitamins, magnesium). Some patients try **low-dose naltrexone (LDN)**, an immune-modulating drug that has shown anecdotal benefit in fibromyalgia and ME/CFS by reducing neuroinflammation. There is also exploration of **antiviral or immunomodulatory therapy** in subsets of ME/CFS: e.g., antivirals (such as valganciclovir) in those with evidence of herpesvirus reactivation, or immune globulin infusions in those with certain immune deficiencies. These remain experimental for the most part. Long COVID clinics similarly use a toolkit of symptom-based treatments: antihistamines and mast cell stabilizers (due to theories of mast cell activation contributing to symptoms), anti-inflammatory supplements (like omega-3, turmeric), graded **breathing and mindfulness exercises** for autonomic calming, and sometimes **metabolic therapies** (some trials are looking at compounds like NAD<sup>+</sup> precursors or amino acid supplements to improve mitochondrial function post-COVID). **Integrative medicine** – incorporating nutrition, acupuncture, meditation, and gentle yoga or tai chi – has a role in many chronic fatigue patients' lives, aiming to restore balance in the absence of a magic bullet cure.

**Astronaut Rehabilitation:** For astronauts, treatment is essentially *comprehensive physical rehabilitation*. Immediately on landing, crew are given IV fluids and salt tablets to combat orthostatic intolerance. They often wear a **G-suit or compression garments** for the first 24–48 hours to prevent blood pooling in the legs. Vestibular training exercises (head movements, balance tasks) are done to hasten neuro-vestibular adaptation. Then, in a structured program, astronauts spend ~2 hours per day with exercise physiologists doing progressively intensifying workouts: treadmill walking that advances to jogging, resistance training to rebuild strength, and flexibility and coordination drills <sup>76</sup>. Cardiovascular activities are carefully monitored so that the astronaut's heart rate/blood pressure response is appropriate – if excessive, they may still be volume-depleted or dysautonomic and need to dial back. The rehabilitation is often tiered in **phases**: Phase 1 (first 1–2 weeks) focuses on basic ambulation, range of motion, and core strength; Phase 2 introduces more strenuous aerobic and resistance work; Phase 3 (by ~week 6) pushes towards pre-flight fitness levels <sup>77</sup>. Because astronauts are highly motivated and otherwise healthy individuals, they usually adhere well and make rapid gains. Any specific issues – e.g. a lingering back pain from a herniated disc or an eye issue from Spaceflight Associated Neuro-ocular Syndrome (SANS) – are handled by appropriate specialists (orthopedists, ophthalmologists) during rehab. In sum, the treatment for spaceflight-related fatigue is essentially the polar opposite of the Victorian rest cure: it is **activity as medicine**, applied systematically.

And it works – as noted, nearly all astronauts are back to baseline by 45 days post-mission <sup>63</sup>, which is a testament to the reversibility of purely physiological deconditioning in a healthy body.

**Bridging the Approaches:** It is enlightening to consider how treatment philosophies have almost come full circle in some ways. The rest cure fell out of favor, yet today’s **“energy envelope” management in CFS (pacing)** is essentially a moderated form of rest therapy – patients are advised to rest after exertion and not overdo activity, albeit not to the extreme of six weeks of bed rest. Conversely, the exercise-for-health idea, once novel in the West cure and now standard in rehabilitation, has to be carefully adapted in conditions like ME/CFS to avoid harm. Modern medicine also brings **psychological therapies** into the mix. CBT has been used in CFS to help patients cope with symptoms and adjust behaviors (though it’s not curative and should not be implied as treating a purely psychological illness – it’s more about coping strategies). In long COVID, supportive psychotherapy or psychiatric care is often needed for the anxiety and depression that can accompany a long illness, and addressing those can indirectly improve overall function. Historical neurasthenia treatment also involved counseling by the physician (though not formal psychotherapy, doctors like Mitchell did impose lifestyle changes and gave reassurance, which is a rudimentary form of therapy). Another modern modality is **autonomic retraining** – for instance, some ME/CFS and POTS patients use tilt-table training or biofeedback to improve autonomic responses, akin to physical therapy for the nervous system. The use of **pharmacotherapy** distinguishes modern practice: we have tools like midodrine (to raise blood pressure) or beta blockers for POTS, or modafinil for fatigue, etc., which historical physicians did not. Still, none of these is a cure, only an aid. Finally, a promising area is **integrative rehabilitation** for long COVID – programs that combine cardiac rehab, neurological rehab, and mindfulness. These often include careful graded activity *plus* breathing exercises (to stimulate the vagus nerve and parasympathetic system), dietary advice (to support gut health and reduce inflammation), and cognitive pacing for those with brain fog (like return-to-work programs with accommodations). This holistic approach is reminiscent of the sanatoria of old, but with more science behind each element.

## Toward Unified Mechanisms and Novel Insights

Examining these conditions side by side suggests that despite different triggers, we may be looking at a common final pathway: a state of **systemic dysregulation or maladaptation** where the normal coordination between systems breaks down. One useful concept is that of **allostatic load**, the cumulative “wear and tear” on the body’s regulatory systems under chronic stress. In CFS and post-viral syndromes, an initial stressor (infection or other insult) may push the system into a state of allostatic overload – for example, an extended period of immune activation and HPA axis strain – resulting in a new homeostatic setpoint that is maladaptive (e.g. low cortisol, chronic inflammation, autonomic imbalance) <sup>21</sup> <sup>26</sup>. Similarly, in neurasthenia the purported cause was chronic stress of modern life overwhelming the nervous system’s capacity – essentially an antiquated description of allostatic load. Astronauts in microgravity experience an acute allostatic hit: multiple systems have to adjust to weightlessness (fluid shifts, bone unloading, psychological stress of confinement). While they can largely revert to normal, interestingly some changes at the cellular level (like epigenetic changes or shifts in microbiome) might persist longer, raising questions about subtle long-term health effects of spaceflight. The fact that *mitochondrial dysfunction* has been identified as a central issue in spaceflight <sup>78</sup> <sup>79</sup> and is strongly suspected in CFS <sup>37</sup> hints at a possible unified mechanism: perhaps the body, under intense stress (be it viral, gravitational, or emotional), induces a hypometabolic, mitochondria-tuned-down state as a protective mechanism – a kind of hibernation or “energy conservation mode.” In evolutionary terms, during severe illness or starvation, reducing energy output could be adaptive (this aligns with Naviaux’s “Cell Danger Response” hypothesis in CFS <sup>37</sup>). However, if this response overshoots or fails to turn off, the result is a chronic fatigue state.

Supporting this, some shared biochemical findings are emerging: for example, one study found that long COVID patients had **persistently reduced serum cortisol** and blunted ACTH (adrenal stimulating hormone) responses, exactly paralleling findings in chronic fatigue syndrome <sup>26</sup> <sup>27</sup> . Such endocrine similarities indicate a common adaptation or injury to the neuroendocrine system. Another overlap is in the **autoimmune realm**: researchers have detected autoantibodies against autonomic nerve receptors in both ME/CFS and long COVID patients, suggesting that an autoimmune process might lock in dysautonomia and interfere with energy metabolism (autoantibodies to  $\beta$ 2-adrenergic and M acetylcholine receptors have been reported in a subset of ME/CFS). There's also the intriguing observation that **women are affected far more than men** in ME/CFS and long COVID, and historically many neurasthenia cases were women (though men certainly had it too, often labeled differently). This points to sexual dimorphism in stress responses or immune function – perhaps estrogen's effects on immunity and cortisol feedback play a role. It's notable that astronauts, a highly selected group, haven't reported sex differences in reconditioning, likely because the triggers (microgravity) affect both sexes similarly and the sample sizes are small; but in chronic inflammatory conditions, women's immune systems tend to react more vigorously (as seen in higher autoimmune disease rates).

Another pattern tying these conditions is **autonomic-autocrine loops**: for instance, chronic low-grade inflammation can impair baroreflex and cause tachycardia; poor sleep (from HPA-axis disturbance) in turn raises inflammation; gut dysbiosis fuels inflammation and can alter neurotransmitters that affect the brain (via the vagus nerve). These vicious circles cut across organ systems. In ME/CFS and long COVID, it may be that an initial immune hit triggers microglial (brain immune cell) activation that never fully resolves, leading to neuroinflammation that disturbs sleep and autonomic centers – a self-sustaining loop. In astronauts, unloading of the cardiovascular system leads to downregulation of baroreceptors and loss of blood volume, which upon re-entry causes OI and stress that temporarily spikes inflammation – a transient loop that is broken by medical intervention and gravity re-exposure. **Systems biology** analyses are increasingly being applied to ME/CFS and long COVID data, using machine learning to find biomarkers that predict illness severity. A recent example is a multivariate cytokine signature that could distinguish CFS patients from controls <sup>44</sup> , or metabolic profiles that can predict long COVID. Such findings are sparking interest in whether a **unified diagnostic panel** could be developed for post-viral and fatigue syndromes, something that would have seemed far-fetched in the neurasthenia era. In fact, Montoya's cytokine study at Stanford suggested the development of a blood test for ME/CFS might be feasible <sup>44</sup> <sup>45</sup> . If so, we might finally have objective confirmation of what patients have long known – that these conditions are grounded in biology, not in “purely mental” realms as skeptics once alleged.

One underappreciated insight from the historical perspective is how **socio-cultural framing** affects both illness and therapy. In the 1800s, neurasthenia was accepted as a real illness of civilized life – it carried a certain prestige and sympathy (albeit with misogynistic overtones for women). Today, ME/CFS had to struggle for decades against stigma and dismissal as “yuppie flu” or psychosomatic illness. The recognition of long COVID by mainstream medicine (because it followed a highly publicized pandemic) has inadvertently shone a light on post-viral CFS and lent it new legitimacy. Now there is significant research funding and interest in these syndromes, which could lead to breakthroughs that benefit all. For example, if researchers find an antiviral or anti-inflammatory that alleviates long COVID symptoms, it might be repurposed for ME/CFS. Already, clinical trials are underway with drugs like interferon, BC007 (an antibody-neutralizing compound), and amphetamines for cognitive issues in long COVID – all potential harbingers of new treatments. Meanwhile, NASA's research into keeping astronauts healthy in space (e.g. mitochondrial protectants, artificial gravity, microbiome probiotics) might yield interventions that could help bedridden patients on Earth. **Cross-pollination of knowledge** is happening: NASA's finding of mitochondrial pathways

has encouraged CFS researchers to look more closely at those pathways; conversely, the decades of ME/CFS literature on autonomic dysfunction and “neurally mediated hypotension” informed some of the approaches to orthostatic intolerance in astronauts and in long COVID patients.

In terms of specific novel interventions, one can speculate: could **mitochondrial modulators** (like NAD<sup>+</sup> boosters or mitochondrial biogenesis stimulators) help both an astronaut during reconditioning and a CFS patient? Possibly – something like nicotinamide riboside might improve cellular energetics in general. Could **vagal nerve stimulation** (being tested in depression and inflammatory bowel disease) reduce the autonomic storm and inflammation in long COVID/CFS? There’s rationale, since increased vagal tone can anti-inflate and stabilize heart rate. Such devices or techniques (even deep breathing exercises) essentially aim to restore autonomic balance – which all these conditions would benefit from. Another insight: **microbiome therapy** – astronauts take probiotics now on missions to mitigate dysbiosis; CFS trials with probiotics have shown some symptom improvements (especially for gut and mood symptoms) <sup>3</sup> <sup>7</sup> . Fecal microbiota transplants (FMT) are even being tried experimentally in some severe long COVID cases on the premise of rebooting the gut-immune axis. This interplay of gut health and systemic energy is something Beard and colleagues anecdotally recognized in “nervous dyspepsia,” and now we may have the tools to actually manipulate it.

Finally, a striking pattern is how **restorative sleep and circadian realignment** seem pivotal for recovery across these conditions. Astronauts often have circadian disruption in orbit; upon return, enforcing normal sleep-wake cycles and getting sunlight helps them recover faster. In ME/CFS and post-viral fatigue, patients often have disordered sleep (inverted cycles, unrefreshing sleep) – approaches like controlled light exposure, melatonin or chronotherapy might gradually rebuild a stronger circadian rhythm, which in turn could normalize HPA and ANS function <sup>80</sup> . Some long COVID clinics focus on sleep optimization as step one. The Victorian rest cure was essentially an enforced period of “restorative” living – albeit taken to an extreme – which surely did help some by allowing extended good sleep (some patients on rest cure reportedly slept 12–14 hours a day after initial insomnia resolved). In our modern go-go culture, a chronic illness patient often does not get that kind of rest without guilt or pressure. Perhaps one takeaway is that *strategic rest* – not abandonment to bed, but measured, high-quality rest – is therapeutic and should be valued alongside active therapies.

In conclusion, the comparative study of these four scenarios – CFS, post-viral syndromes, astronaut reconditioning, and neurasthenia – reveals a tapestry of interwoven physiological threads. Each condition highlights a different facet of the body’s dynamic equilibrium: the response to infection, the response to microgravity, the response to chronic stress, and the attempt to recover from each. All point to the idea that fatigue syndromes are not isolated to one organ but are emergent properties of a perturbed network involving brain, immune system, hormones, autonomic nerves, and metabolism. Where one leads, the others offer clues. By understanding their commonalities, we move closer to general principles of how the body copes with extreme strain and how it sometimes fails to find its way back to the stable center. Modern science, armed with both cutting-edge molecular techniques and lessons from history, is now poised to unravel these mysteries. The hope is that unified insights (such as identifying a shared inflammatory or metabolic biomarker) will lead to unified *treatments* – interventions that can reboot the system, whether it’s a drug that targets dysfunctional metabolism or a neuromodulation that resets autonomic tone. What is increasingly clear is that these conditions are real, multi-factorial illnesses – not figments of imagination or simple laziness (as neurasthenics were sometimes accused, or CFS patients more recently). As we forge ahead, patients from the Victorian sickroom to the space capsule can all benefit from the growing

understanding that fatigue is the final common pathway of many assaults on human physiology, and that reclaiming energy requires respecting the complex interplay of body systems.

## Conclusion

Across centuries and contexts, the phenomena of chronic fatigue – whether labeled neurasthenia in a 19th-century socialite, post-viral syndrome in a 21st-century pandemic survivor, or physical deconditioning in a spacefarer – exhibit remarkable concordance in their multi-system reach. All entail a breakdown in the delicate balance of the autonomic, endocrine, immune, and metabolic systems, leading to a state of diminished vigor and impaired homeostasis. They diverge in triggers and acute features: infections and inflammation in one, microgravity and orthostatic stress in another, psychological stress and “modern life” in the historical narrative. Yet, the body’s responses show rhyming patterns – the gut’s flora shifting, the heart racing or blood pressure faltering, the adrenal output faltering after an initial surge, the cells’ mitochondria dialing down energy production. Treatments too have oscillated between extremes of rest and exertion, gradually converging on nuanced strategies that emphasize personalized pacing, rehabilitation, and restoration of system integrity.

By comparing these syndromes, we glean that fatigue is not a trivial symptom but a complex **signal of systemic disharmony**, and recovery often involves re-calibrating the entire organism. The historical rest cure recognized the unity of mind and body stress, albeit with crude tools; modern medicine is relearning that lesson – that a patient with long COVID or ME/CFS may need a combination of biomedical and supportive therapies addressing mind, gut, hormones, and heart. Space medicine contributes the optimistic insight that even severe physiological perturbations can be recovered from if we understand the mechanisms and apply targeted countermeasures. In the end, the shared and divergent features of these conditions provide a richer understanding of human adaptive capacity. They suggest that there are common pathways – perhaps final convergent pathways of **chronic energy insufficiency and autonomic dysregulation** – that could be therapeutically targeted, no matter the initial cause. And they remind us, as Beard and Mitchell knew, and as NASA doctors know today, that **recovery is a process across multiple systems and one that requires patience, care, and often a holistic approach**. The converging research on CFS, long COVID, and even astronaut health is cause for optimism: what we learn in one arena can illuminate the others. In peeling back the layers of these complex syndromes, we are inching closer to therapies that can reboot the human body’s remarkable, and sometimes vulnerable, equilibrium.

### Sources:

1. Wang JH *et al.* “Clinical evidence of the link between gut microbiome and ME/CFS: a retrospective review.” *J Transl Med.* 2024 <sup>1</sup> <sup>81</sup> .
2. Naviaux RK *et al.* “Metabolic features of chronic fatigue syndrome.” *PNAS.* 2016 <sup>37</sup> .
3. Martín-Martínez E *et al.* “Dysautonomia in ME/CFS and Long COVID.” *Sci Rep.* 2023 <sup>17</sup> .
4. Loomba RS *et al.* “Orthostatic intolerance after spaceflight.” *NPJ Microgravity.* 2022 <sup>19</sup> .
5. Papadopoulos AS & Cleare AJ. “Hypothalamic–pituitary–adrenal axis dysfunction in CFS.” *Nat Rev Endocrinol.* 2012 <sup>21</sup> .
6. Zhang YD *et al.* “HPA axis changes in CFS and treatments.” *Front Endocrinol.* 2024 <sup>22</sup> .
7. Crucian BE *et al.* “Herpes virus reactivation in astronauts during spaceflight.” *Front Microbiol.* 2016 <sup>30</sup> <sup>31</sup> .
8. Tavares F *et al.* “Mitochondrial changes key to health problems in space.” NASA Article, 2020 <sup>78</sup> <sup>79</sup> .

9. Montoya JG *et al.* "Cytokine signature associated with disease severity in ME/CFS." *PNAS*. 2017 (Stanford News) 44 45 .
10. Komaroff AL & Lipkin WI. "Insights from metagenomic, proteomic, and cytokine studies in ME/CFS." *Clin Infect Dis*. 2021 45 .
11. Huang C *et al.* "6-month and 2-year outcomes in COVID-19 survivors." *Lancet*. 2021 & 2022 62 61 .
12. Mehta SK *et al.* "Latent virus reactivation in astronauts on ISS." *J Infect Dis*. 2014 30 33 .
13. Newton JL *et al.* "Symptoms of autonomic dysfunction in CFS." *QJM*. 2007 13 .
14. Mitchell SW. **Fat and Blood: An Essay on the Treatment of Certain Forms of Neurasthenia**. 1877 (on rest cure) 66 43 .
15. Shorter E. **From Paralysis to Fatigue**. 1992 (history of neurasthenia).
16. National Institute for Health and Care Excellence (NICE). **ME/CFS: Diagnosis and Management Guideline NG206**. 2021 (recommending against GET) 74 75 .
17. Blaker-Lee A *et al.* "Neurasthenia gastrica revisited: nerve-gut interactions in 1880–1920." *Med Hist*. 2018 12 11 .
18. Poole L *et al.* "Allostatic load in chronic fatigue syndrome." *Psychoneuroendocrinology*. 2019 21 82 .
19. Davis HE *et al.* "Long COVID: major findings and mechanisms." *Nat Rev Microbiol*. 2023 26 .

---

1 2 3 81 Clinical evidence of the link between gut microbiome and myalgic encephalomyelitis/chronic fatigue syndrome: a retrospective review - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10908121/>

4 5 6 7 55 56 61 62 The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID | Signal Transduction and Targeted Therapy

<https://www.nature.com/articles/s41392-023-01640-z>

8 9 10 Understanding the Complexities and Changes of the Astronaut Microbiome for Successful Long-Duration Space Missions - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC9031868/>

11 12 20 34 35 'Neurasthenia gastrica' revisited: perceptions of nerve-gut interactions in nervous exhaustion, 1880–1920 - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC6327930/>

13 14 15 16 Autonomic Phenotypes in Chronic Fatigue Syndrome (CFS) Are Associated with Illness Severity: A Cluster Analysis - PMC

<https://pmc.ncbi.nlm.nih.gov/articles/PMC7464864/>

17 Long-COVID autonomic syndrome in working age and work ability impairment | Scientific Reports

<https://www.nature.com/articles/s41598-024-61455-y>

18 Yes, Long COVID Can Cause POTS and Dysautonomia - Cognitive FX

<https://www.cognitivefxusa.com/blog/long-covid-pots-and-dysautonomia>

19 Computational modeling of orthostatic intolerance for travel to Mars | npj Microgravity

<https://www.nature.com/articles/s41526-022-00219-2>

21 23 24 25 Hypothalamic–pituitary–adrenal axis dysfunction in chronic fatigue syndrome | Nature Reviews Endocrinology

<https://www.nature.com/articles/nrendo.2011.153>



- 22 53 54 **Frontiers | Research progress in the treatment of chronic fatigue syndrome through interventions targeting the hypothalamus-pituitary-adrenal axis**  
<https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1373748/full>
- 26 27 50 58 59 **Long COVID: major findings, mechanisms and recommendations - PMC**  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC9839201/>
- 28 29 **Part IV: Long COVID and HPA Axis Dysregulation**  
<https://www.zrtlab.com/blog/archive/long-covid-and-hpa-axis-dysregulation/>
- 30 31 33 **Herpes Virus Reactivation in Astronauts During Spaceflight and Its Application on Earth - PMC**  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6374706/>
- 32 **[PDF] Long-term human spaceflight and inflammaging - DLR**  
[https://elib.dlr.de/194447/1/ME-SBA-2023-Capri\\_Moeller\\_etal\\_2023ARR-finalpdf.pdf](https://elib.dlr.de/194447/1/ME-SBA-2023-Capri_Moeller_etal_2023ARR-finalpdf.pdf)
- 36 67 73 **The 'Father of American Neurology' Prescribed Women Months of Motionless Milk-Drinking - Gastro Obscura**  
<https://www.atlasobscura.com/articles/what-was-the-rest-cure>
- 37 **Metabolic features of chronic fatigue syndrome - PMC**  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC5027464/>
- 38 39 40 41 42 78 79 **Mitochondrial Changes Key to Health Problems in Space - NASA**  
<https://www.nasa.gov/humans-in-space/mitochondrial-changes-key-to-health-problems-in-space/>
- 43 66 69 70 71 72 **From nerves to neuroses | Science Museum**  
<https://www.sciencemuseum.org.uk/objects-and-stories/medicine/nerves-neuroses>
- 44 45 52 60 **Researchers identify biomarkers associated with chronic fatigue syndrome severity | Medical Center Development | Stanford Medicine**  
<https://medicalgiving.stanford.edu/news/researchers-id-biomarkers-associated-with-chronic-fatigue-syndrome.html>
- 46 **Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit ...**  
<https://www.jci.org/articles/view/132185>
- 47 **Chronic fatigue syndrome and circulating cytokines: A systematic ...**  
<https://www.sciencedirect.com/science/article/abs/pii/S088915911500238X>
- 48 **Cytokine signature associated with disease severity in chronic ...**  
<https://www.pnas.org/doi/10.1073/pnas.1710519114>
- 49 **Molecular Mechanisms of Neuroinflammation in ME/CFS and Long ...**  
<https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.877772/full>
- 51 64 65 **Spaceflight alters host-gut microbiota interactions | npj Biofilms and Microbiomes**  
<https://www.nature.com/articles/s41522-024-00545-1>
- 57 **ME/CFS and Long COVID share similar symptoms and biological ...**  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10278546/>
- 63 **NASA astronauts Sunita Williams and Butch Wilmore's 45-day ...**  
<https://timesofindia.indiatimes.com/science/nasa-astronauts-sunita-williams-and-butch-wilmores-45-day-rehabilitation-how-do-astronauts-recover-after-long-space-missions/articleshow/119437874.cms>
- 68 **From rest cure to work cure - American Psychological Association**  
<https://www.apa.org/monitor/2010/05/cures>

74 Neurasthenia - Wikipedia

<https://en.wikipedia.org/wiki/Neurasthenia>

75 NEURASTHENIA AND THE REST CURE. - JAMA Network

<https://jamanetwork.com/journals/jama/fullarticle/477358>

76 77 45-day rehabilitation: How NASA astronauts will adjust to life on Earth

<https://kashmirreader.com/2025/03/20/45-day-rehabilitation-how-nasa-astronauts-will-adjust-to-life-on-earth/>

80 Long-term spaceflight composite stress induces depression and ...

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10632511/>

82 Allostatic overload in myalgic encephalomyelitis/chronic fatigue ...

<https://www.sciencedirect.com/science/article/abs/pii/S0306987713003137>